Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 November 1992Website:
http://www.ligand.comNext earnings report:
27 February 2025Last dividends:
02 July 2010Next dividends:
N/APrice
pre-market | 73 min agoDividend
Analysts recommendations
Institutional Ownership
LGND Latest News
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - Chief Executive Officer Karen Reeves - Senior Vice President of Investments and Head of Clinical Strategy Tavo Espinoza - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Douglas Miehm - RBC Capital Markets Joseph Pantginis - Wainwright Trevor Allred - Oppenheimer John Vandermosten - Zach Small Capital Research Operator Good morning. My name is Aaron, and I will be your conference operator for today.
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as MSD outside the United States and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE™, previously known as V116, a 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population. The indication for pneumococcal pneumonia is under accelerat.
Ligand (LGND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
The average of price targets set by Wall Street analysts indicates a potential upside of 32.3% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ligand (LGND) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming investor conferences: Craig-Hallum Institutional Investor Conference (Minneapolis). Management will participate in one-on-one meetings on May 29, 2024. Goldman Sachs Global Healthcare Conference (Miami). Management will present on June 12, 2024 at 4:00 p.m. ET. Managemen.
There is increasing optimism about Ligand's earnings potential, leading to its upgrade to a Zacks Rank #1 (Strong Buy) and potential for higher movement in the stock.
Royalty aggregators such as Royalty Pharma, Ligand, and XOMA are becoming increasingly popular in the biotech sector. They acquire royalty rights to pharmaceutical products from biotech companies, offering them immediate cash in exchange. This arrangement enables biotech firms to secure funding for research and development, while the aggregators profit from their investment.
The average price targets from analysts on Wall Street suggest a possible increase of 45.6% in Ligand (LGND). Though the reliability of this metric is uncertain, the optimistic trend in earnings estimates could lead to a rise in the stock.
What type of business is Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that is involved in the development and acquisition of technologies that help pharmaceutical companies worldwide to discover and develop drugs. Ligand uses research technologies for antibody discovery, structure-based drug design, and more. The company was founded in 1987, with headquarters located in San Diego, California. Currently, Ligand has partnership and licensing agreements with more than 120 pharmaceutical and biotechnology companies. Over 200 different programs are at various stages of commercialization and development and are fully funded by collaboration partners and licensees.
What sector is Ligand Pharmaceuticals Incorporated in?
Ligand Pharmaceuticals Incorporated is in the Healthcare sector
What industry is Ligand Pharmaceuticals Incorporated in?
Ligand Pharmaceuticals Incorporated is in the Biotechnology industry
What country is Ligand Pharmaceuticals Incorporated from?
Ligand Pharmaceuticals Incorporated is headquartered in United States
When did Ligand Pharmaceuticals Incorporated go public?
Ligand Pharmaceuticals Incorporated initial public offering (IPO) was on 18 November 1992
What is Ligand Pharmaceuticals Incorporated website?
https://www.ligand.com
Is Ligand Pharmaceuticals Incorporated in the S&P 500?
No, Ligand Pharmaceuticals Incorporated is not included in the S&P 500 index
Is Ligand Pharmaceuticals Incorporated in the NASDAQ 100?
No, Ligand Pharmaceuticals Incorporated is not included in the NASDAQ 100 index
Is Ligand Pharmaceuticals Incorporated in the Dow Jones?
No, Ligand Pharmaceuticals Incorporated is not included in the Dow Jones index
When was Ligand Pharmaceuticals Incorporated the previous earnings report?
No data
When does Ligand Pharmaceuticals Incorporated earnings report?
The next expected earnings date for Ligand Pharmaceuticals Incorporated is 27 February 2025